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The CRISPR-associated endonuclease Cas9 can be
targeted to specific genomic loci by single guide
RNAs (sgRNAs). Here, we report the crystal structure
of Streptococcus pyogenes Cas9 in complex with
sgRNA and its target DNA at 2.5 A˚ resolution. The
structure revealed a bilobed architecture composed
of target recognition and nuclease lobes, accommo-
dating the sgRNA:DNA heteroduplex in a positively
charged groove at their interface. Whereas the
recognition lobe is essential for binding sgRNA and
DNA, the nuclease lobe contains the HNH and
RuvC nuclease domains, which are properly posi-
tioned for cleavage of the complementary and
noncomplementary strands of the target DNA,
respectively. The nuclease lobe also contains a
carboxyl-terminal domain responsible for the inter-
action with the protospacer adjacent motif (PAM).
This high-resolution structure and accompanying
functional analyses have revealed the molecular
mechanism of RNA-guided DNA targeting by Cas9,
thus paving the way for the rational design of new,
versatile genome-editing technologies.
INTRODUCTION
The CRISPR (clustered regularly interspaced short palindromic
repeat)-Cas system is a naturally occurring, adaptive microbial
immune system for defense against invading phages and other
mobile genetic elements (Deveau et al., 2010; Horvath and
Barrangou, 2010; Marraffini and Sontheimer, 2010; Terns and
Terns, 2011). Three types (I–III) of CRISPR-Cas systems havebeen functionally identified across a wide range of microbial
species (Barrangou et al., 2007; Brouns et al., 2008; Marraffini
and Sontheimer, 2008), and each contains a cluster of
CRISPR-associated (Cas) genes and its corresponding CRISPR
array. These characteristic CRISPR arrays consist of repetitive
sequences (direct repeats, referred to as repeats) interspaced
by short stretches of nonrepetitive sequences (spacers) derived
from short segments of foreign genetic material (protospacers).
The CRISPR array is transcribed and processed into short
CRISPR RNAs (crRNAs), which direct the Cas proteins to the
target nucleic acids via Watson-Crick base pairing to facilitate
nucleic acid destruction.
The type I and III CRISPR systems utilize ensembles of Cas
proteins complexed with crRNAs to mediate the recognition
and subsequent degradation of target nucleic acids (Spilman
et al., 2013; Wiedenheft et al., 2011). In contrast, the type II
CRISPR system recognizes and cleaves the target DNA (Gar-
neau et al., 2010) via the RNA-guided endonuclease Cas9 (Sap-
ranauskas et al., 2011) along with two noncoding RNAs, the
crRNA and the trans-activating crRNA (tracrRNA) (Deltcheva
et al., 2011). The crRNA hybridizes with the tracrRNA to form a
crRNA:tracrRNA duplex, which is loaded onto Cas9 to direct
the cleavage of cognate DNA sequences bearing appropriate
protospacer-adjacent motifs (PAM) (Mojica et al., 2009). Cas9
contains two nuclease domains, HNH and RuvC, which cleave
the DNA strands that are complementary and noncomplemen-
tary to the 20 nucleotide (nt) guide sequence in crRNAs, respec-
tively (Gasiunas et al., 2012; Jinek et al., 2012).
The type II CRISPR system was the first to be adapted for
facilitating genome editing in eukaryotic cells (Cong et al.,
2013; Mali et al., 2013b). The Cas9 protein from Streptococcus
pyogenes, along with a single guide RNA (sgRNA), a synthetic
fusion of crRNA and tracrRNA (Jinek et al., 2012), could be
programmed to cleave virtually any sequence preceding a 50-
NGG-30 PAM sequence in mammalian cells (Cong et al., 2013;Cell 156, 935–949, February 27, 2014 ª2014 Elsevier Inc. 935
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Mali et al., 2013b). This unprecedented flexibility has enabled a
broad range of applications, including rapid generation of genet-
ically modified cells and animal models (Gratz et al., 2013;
Hwang et al., 2013; Wang et al., 2013; Yang et al., 2013) and
genome-scale genetic screening (Shalem et al., 2014; Wang
et al., 2014).
However, despite the brisk progress in the development of
Cas9 technology, the mechanism by which the Cas9-sgRNA
complex recognizes and cleaves its target DNA remains to be
elucidated. Biochemical analyses at the domain levels have
enabled site-specific engineering to convert the native Cas9
into a DNA-nicking enzyme (Gasiunas et al., 2012; Jinek et al.,
2012; Sapranauskas et al., 2011) that facilitates homology-
directed repair in eukaryotic cells (Cong et al., 2013; Mali et al.,
2013b) and cleaves DNA with improved specificity, given appro-
priately paired sgRNAs (Mali et al., 2013a; Ran et al., 2013).
Moreover, a catalytically inactive Cas9 can serve as an RNA-
guided DNA-binding platform to target effector domains and
modulate endogenous transcription (Gilbert et al., 2013; Koner-
mann et al., 2013; Maeder et al., 2013; Perez-Pinera et al., 2013;
Qi et al., 2013). These advances in Cas9 engineering represent
just the first steps toward fully realizing the potential of this
flexible RNA-guided genome positioning system. Precise struc-
tural information about Cas9 will thus not only enhance our
understanding of how this elegant RNA-guided, adaptive micro-
bial immune system functions, but will also facilitate further
improvements in the Cas9 targeting specificity, the in vitro and
in vivo delivery, and the engineering of Cas9 for novel functions
and optimized features.
Here, we report the crystal structure of S. pyogenes Cas9 in
complex with sgRNA and its target DNA at 2.5 A˚ resolution.
This high-resolution structure, along with functional analyses,
reveals the key functional interactions that integrate the guide
RNA, the target DNA, and the Cas9 protein, thus paving the
way toward enhancing Cas9 function as well as engineering
novel applications.
RESULTS
Overall Structure of the Cas9-sgRNA-DNA Ternary
Complex
We solved the crystal structure of full-length S. pyogenes Cas9
(residues 1–1368; D10A/C80L/C574E/H840A), in complex with
a 98 nt sgRNA and a 23 nt target DNA, at 2.5 A˚ resolution by
the single-wavelength anomalous dispersion (SAD) method,
using a SeMet-labeled protein (Figure 1 and Figure S1 and Table
S1 available online). To improve the solution behavior of Cas9,
we replaced two less-conserved cysteine residues (Cys80Figure 1. Overall Structure of the Cas9-sgRNA-DNA Ternary Complex
(A) Domain organization of S. pyogenes Cas9. BH, bridge helix.
(B) Schematic representation of the sgRNA:target DNA complex.
(C) Ribbon representation of the Cas9-sgRNA-DNA complex. Disordered linkers
(D) Surface representation of the Cas9-sgRNA-DNA complex. The active sites o
circles.
(E) Electrostatic surface potential of Cas9. The HNH domain is omitted for c
cuemol.org).
See also Figures S1 and S2 and Table S1.and Cys574) with leucine and glutamic acid, respectively. This
C80L/C574E mutant retained the ability to efficiently cleave
genomic DNA in human embryonic kidney 293FT (HEK293FT)
cells, confirming that these mutations have no effects on the
Cas9 nuclease function (Figure S2). Additionally, to prevent
target DNA cleavage during crystallization, we replaced two
catalytic residues, Asp10 from the RuvC domain and His840
from the HNH domain, with alanines.
The crystallographic asymmetric unit contained two Cas9-
sgRNA-DNA ternary complexes (Mol A and Mol B). Although
there are conformational differences between the two com-
plexes, the sgRNA and the DNA are recognized by Cas9 in
similar manners. Most notably, whereas the HNH domain in
Mol A is connected to the RuvC domain by a disordered linker,
the HNH domain in Mol B is not visible in the electron density
map, indicating the flexible nature of the HNH domain. Thus,
we will first describe the structural features of Mol A unless
otherwise stated and will then discuss the structural differences
between the two complexes, which suggest the conformational
flexibility of Cas9.
The crystal structure revealed that Cas9 consists of two lobes:
a recognition (REC) lobe and a nuclease (NUC) lobe (Figures 1A–
1D). The REC lobe can be divided into three regions, a long a
helix referred to as the bridge helix (residues 60–93), the REC1
(residues 94–179 and 308–713) domain, and the REC2 (residues
180–307) domain (Figures 1A–1D). The NUC lobe consists of the
RuvC (residues 1–59, 718–769, and 909–1098), HNH (residues
775–908), and PAM-interacting (PI) (residues 1099–1368) do-
mains (Figures 1A–D). The negatively charged sgRNA:target
DNA heteroduplex is accommodated in a positively charged
groove at the interface between the REC and NUC lobes
(Figure 1E). In the NUC lobe, the RuvC domain is assembled
from the three split RuvC motifs (RuvC I–III) and interfaces with
the PI domain to form a positively charged surface that interacts
with the 30 tail of the sgRNA (Figure 1E). The HNH domain lies
between the RuvC II–III motifs and forms only a few contacts
with the rest of the protein.
The REC Lobe Interacts with the Repeat:Anti-Repeat
Duplex
The REC lobe includes the REC1 and REC2 domains. REC1
adopts an elongated, a-helical structure comprising 25 a helices
(a2–a5 and a12–a32) and two b sheets (b6 and b10 and b7–b9),
whereas REC2 adopts a six-helix bundle structure (a6–a11)
(Figures 2A and S3). A Dali search (Holm and Rosenstro¨m,
2010) revealed that the REC lobe does not share structural
similarity with other known proteins, indicating that it is a
Cas9-specific functional domain.are shown as red dotted lines.
f the RuvC (D10A) and HNH (H840A) domains are indicated by dashed yellow
larity. Molecular graphic images were prepared using CueMol (http://www.
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Figure 2. REC Lobe and PI Domain
(A) Structure of the REC lobe. The REC2 domain
and the bridge helix are colored dark gray and
green, respectively. The REC1 domain is colored
gray, with the repeat-interacting and anti-repeat-
interacting regions colored pale blue and pink,
respectively. The bound sgRNA:DNA is shown as
a semitransparent ribbon representation.
(B) Mutational analysis of the REC lobe. Sche-
matics show the truncation mutants. The bar
graph shows indel mutations generated by the
truncation mutants, measured by the SURVEYOR
assay. n = 3; error bars show mean ± SEM; N.D.,
not detectable.
(C) Western blot showing the expression of the
truncation mutants in HEK293FT cells.
(D) Structure of the PI domain. The bound sgRNA
is shown as a semitransparent ribbon represen-
tation.
(E) Mutational analysis of the PI domain. Sche-
matics show wild-type SpCas9 and St3Cas9,
chimeric Sp-St3Cas9 and St3-SpCas9, and the
SpCas9 PI domain truncation mutant. Cas9s
were assayed for indel generation at target sites
upstream of either NGG (left bar graph) or NGGNG
(right bar graph) PAMs. n = 3; error bars show
mean ± SEM; N.D., not detectable; N.A., not
assayed.
See also Figures S3–S5.The REC lobe is one of the least conserved regions across
the three Cas9 families within the type II CRISPR system (IIA,
IIB, and IIC), and many Cas9 orthologs contain significantly
shorter REC lobes (Figures S4 and S5). In the present structure,
the REC2 domain does not contact the bound guide:target
heteroduplex. We thus hypothesized that truncations in the938 Cell 156, 935–949, February 27, 2014 ª2014 Elsevier Inc.REC lobe could be tolerated. As
expected, a Cas9 mutant lacking the
REC2 domain (D175–307) retained
50% of the wild-type Cas9 activity
(Figure 2B), indicating that the REC2
domain is not critical for DNA cleavage.
The lower cleavage efficiency may be
attributed in part to the reduced expres-
sion levels of the D175–307 mutant
relative to that of the wild-type protein
(Figure 2C). In striking contrast, the dele-
tion of either the repeat-interacting region
(D97–150) or the anti-repeat-interacting
region (D312–409) of the REC1 domain
abolished the DNA cleavage activity
(Figure 2B), indicating that the recognition
of the repeat:anti-repeat duplex by the
REC1 domain is critical for the Cas9
function.
The PAM-Interacting Domain
Confers PAM Specificity
The NUC lobe contains the PAM-inter-
acting (PI) domain, which forms anelongated structure comprising seven a helices (a46–a52), a
three-stranded antiparallel b sheet (b18–b20), a five-stranded
antiparallel b sheet (b21–b23, b26, and b27), and a two-stranded
antiparallel b sheet (b24 and b25) (Figures 2D and S3). Similar
to the REC lobe, the PI domain also adopts a novel protein fold
that is unique to the Cas9 family.
The locations of the bound complementary DNA strand and
the active site of the RuvC domain in the present structure
suggested that the PI domain is positioned to recognize the
PAM sequence on the noncomplementary DNA strand. We
tested whether the replacement of the PI domain of
S. pyogenes Cas9 (SpCas9; Cas9 in this study) with that of an
orthologous Cas9 protein, recognizing a different PAM, would
be sufficient to alter their PAM specificities. The Streptococcus
thermophilus CRISPR-3 Cas9 (St3Cas9) shares 60%
sequence identity with SpCas9. Although their crRNA repeats
and tracrRNAs are interchangeable (Fonfara et al., 2013),
SpCas9 and St3Cas9 require different PAM sequences (50-
NGG-30 for SpCas9 and 50-NGGNG-30 for St3Cas9) for target
DNA cleavage (Fonfara et al., 2013).
We swapped their PI domains to generate two chimeras—
Sp-St3Cas9 (SpCas9 with the PI domain of St3Cas9) and
St3-SpCas9 (St3Cas9 with the PI domain of SpCas9)—and
examined their cleavage activities for target DNA sequences
bearing 50-NGG-30 PAM (50-GGGCT-30) or 50-NGGNG-30 PAM
(50-GGGCG-30) (Figure 2E). SpCas9 and St3-SpCas9, but not
St3Cas9, cleaved the target DNA with 50-NGG-30 PAM (Fig-
ure 2E), indicating that the PI domain of SpCas9 is required for
the recognition of 50-NGG-30 PAM and is sufficient to alter the
PAM specificity of St3Cas9. Sp-St3Cas9 retained the cleavage
activity for the target DNA with 50-NGG-30 PAM, albeit at a lower
level than that of SpCas9 (Figure 2E). Additionally, the deletion of
the PI domain (D1099–1368) abolished the cleavage activity
(Figure 2E), indicating that the PI domain is critical for the Cas9
function. These results revealed that the PI domain is a major
determinant of the PAM specificity.
The RuvC Domain Has an RNase H fold
The RuvC domain consists of a six-stranded mixed b sheet (b1,
b2, b5, b11, b14, and b17) flanked by a helices (a33, a34, and
a39–a45) and two additional two-stranded antiparallel b sheets
(b3/b4 and b15/b16) (Figures 3A and S3). It shares structural
similarity with the retroviral integrase superfamily members char-
acterized by an RNase H fold, such as Escherichia coli RuvC
(Ariyoshi et al., 1994) (PDB code 1HJR, 14% identity, root-
mean-square deviation [rmsd] of 3.6 A˚ for 126 equivalent Ca
atoms) and Thermus thermophilus RuvC (Go´recka et al., 2013)
(PDB code 4LD0, 12% identity, rmsd of 3.4 A˚ for 131 equivalent
Ca atoms) (Figure 3B). The RuvC nucleases have four catalytic
residues (e.g., Asp7, Glu70, His143, and Asp146 in
T. thermophilus RuvC) and cleave Holliday junctions through a
two-metal mechanism (Ariyoshi et al., 1994; Chen et al., 2013;
Go´recka et al., 2013). Asp10 (Ala), Glu762, His983, and
Asp986 of the Cas9 RuvC domain are located at positions similar
to those of the catalytic residues of T. thermophilus RuvC (Fig-
ures 3A and 3B), consistent with previous results showing that
Asp10 is critical for the cleavage of the noncomplementary
DNA strand and that Cas9 requires Mg2+ ions for the cleavage
activity (Gasiunas et al., 2012; Jinek et al., 2012). Moreover,
the alanine substitution of Glu762, His983, or Asp986 also con-
verted Cas9 into a nickase (Figures 3C and 3D). Each nickase
mutant was able to facilitate targeted double-strand breaks
using a pair of juxtaposed sgRNAs (Figures 3C, 3D, and Table
S2), as previously demonstrated with the D10A nickase (Ranet al., 2013). This combination of structural observations and
mutational analyses suggested that the Cas9 RuvC domain
cleaves the noncomplementary strand of the target DNA through
the two-metal mechanism, as previously observed for other
retroviral integrase superfamily nucleases.
It is important to note that there are key structural dissimilar-
ities between the Cas9 RuvC domain and the RuvC nucleases,
which explain their functional differences. Unlike the Cas9
RuvC domain, the RuvC nucleases form dimers and recognize
Holliday junctions (Go´recka et al., 2013) (Figure 3B). In addition
to the conserved RNase H fold, the Cas9 RuvC domain has other
structural elements involved in interactions with the guide:target
heteroduplex (an end-capping loop between a42 and a43) and
the PI domain/stem loop 3 (b hairpin formed by b3 and b4)
(Figure 3A).
The HNH Domain Has a bba-Metal Fold
The HNH domain comprises a two-stranded antiparallel b sheet
(b12 and b13) flanked by four a helices (a35–a38) (Figure 3E). It
shares structural similarity with the HNH endonucleases char-
acterized by a bba-metal fold, such as phage T4 endonuclease
VII (Endo VII) (Biertu¨mpfel et al., 2007) (PDB code 2QNC, 20%
identity, rmsd of 2.7 A˚ for 61 equivalent Ca atoms) and Vibrio
vulnificus nuclease (Li et al., 2003) (PDB code 1OUP, 8% identity,
rmsd of 2.7 A˚ for 77 equivalent Ca atoms) (Figure 3F). HNH nucle-
ases have three catalytic residues (e.g., Asp40, His41, and
Asn62 in Endo VII) and cleave nucleic acid substrates through
a single-metal mechanism (Biertu¨mpfel et al., 2007; Li et al.,
2003). In the structure of the Endo VII N62D mutant in complex
with a Holliday junction, a Mg2+ ion is coordinated by Asp40,
Asp62, and the oxygen atoms of the scissile phosphate group
of the substrate, and His41 acts as a general base to activate a
water molecule for catalysis (Figure 3F). Asp839, His840, and
Asn863 of the Cas9 HNH domain correspond to Asp40, His41,
and Asn62 of Endo VII, respectively (Figure 3E), consistent with
the observation that His840 is critical for the cleavage of the
complementary DNA strand (Gasiunas et al., 2012; Jinek et al.,
2012). The N863A mutant functions as a nickase (Figures 3C
and 3D), indicating that Asn863 participates in catalysis. These
observations suggested that the Cas9 HNH domain may cleave
the complementary strand of the target DNA through a single-
metal mechanism, as observed for other HNH superfamily nucle-
ases. However, in the present structure, Asn863 of Cas9 is
located at a different position from that of Asn62 in Endo VII,
whereas Asp839 and His840 (Ala) of Cas9 are located at
positions similar to those of Asp40 andHis41 in Endo VII, respec-
tively (Figure 3G). This might be due to the absence of divalent
ions, such as Mg2+, in our crystallization solution, and Asn863
may point toward the active site and participate in catalysis.
Although the HNH domain shares a bba-metal fold with other
HNN endonucleases, their overall structures are distinct (Figures
3E and 3F), consistent with the differences in their substrate
specificities.
The sgRNA:DNA Complex Adopts a T-Shaped
Architecture
The sgRNA consists of crRNA- and tracrRNA-derived se-
quences connected by an artificial tetraloop (Figure 4A). TheCell 156, 935–949, February 27, 2014 ª2014 Elsevier Inc. 939
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(A) Structure of the RuvC domain. The core structure of the RNase H fold is highlighted in cyan. The active site residues are shown as stick models.
(B) Structure of the T. thermophilus RuvC dimer in complex with a Holliday junction (PDB ID 4LD0). The two protomers are colored cyan and gray, respectively.
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See also Table S2.
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crRNA sequence can be divided into guide (20 nt) and repeat (12
nt) regions, whereas the tracrRNA sequence can be divided into
anti-repeat (14 nt) and three tracrRNA stem loops (Figure 4A).
The crystal structure revealed that the sgRNA binds the target
DNA to form a T-shaped architecture comprising a guide:target
heteroduplex, a repeat:anti-repeat duplex, and stem loops 1–3
(Figures 4A and 4B). The repeat:anti-repeat duplex and stem
loop 1 are connected by a single nucleotide (A51), whereas
stem loops 1 and 2 are connected by a 5 nt single-stranded linker
(nucleotides 63–67).
The guide (nucleotides 1–20) and target DNA (nucleotides 10–
200) form the guide:target heteroduplex via 20 Watson-Crick
base pairs (Figures 4A and 4B). The conformation of the hetero-
duplex is distorted from that of the canonical A-form RNA duplex
(Figure S6). The repeat (nucleotides 21–32) and the anti-repeat
(nucleotides 37–50) form the repeat:anti-repeat duplex via nine
Watson-Crick base pairs (U22:A49–A26:U45 and G29:C40–
A32:U37) (Figures 4A and 4B). Within this region, G27, A28,
A41, A42, G43, and U44 are unpaired, with A28 and U44 flipped
out from the duplex (Figure 4C). The G27 and A41 nucleobases
stack with the A26:U45 and G29:C40 pairs, respectively, and
the 2-amino group of G27 interacts with the backbone phos-
phate group between G43 and U44, stabilizing the duplex struc-
ture (Figure 4C). G21 and U50 form a wobble base pair at the
three-way junction between the guide:target heteroduplex/
repeat:anti-repeat duplex and stem loop 1, contributing to the
formation of the T-shaped architecture (Figure 4C).
As expected from the RNA fold predictions based on the
nucleotide sequence, the tracrRNA 30 tail (nucleotides 68–81
and 82–96) forms stem loops 2 and 3 via four and six Watson-
Crick base pairs (A69:U80–U72:A77 and G82:C96–G87:C91),
respectively (Figures 4A and 4B). In addition, nucleotides 52–
62 form the newly detected stem loop (stem loop 1) via three
Watson-Crick base pairs (G53:C61, G54:C60, and C55:G58),
with U59 flipped out from the stem (Figures 4A and 4B). Stem
loop 1 is stabilized by the G62-G53:C61 stacking interaction
and the G62-A51/A52 polar interactions (Figure 4C).
The guide:target and repeat:anti-repeat duplexes are deeply
buried in a positively charged groove at the interface of the two
lobes, whereas the rest of the sgRNA extensively interacts with
the positively charged surface on the back side of the protein
(Figure 1E). In Mol A, the three nucleotides at the 50 end of the
target DNA (30-ACC-50, complementary to the PAM) are not
visible in the electron density map. Although the two adjacent
nucleotides (30-AC-50) in Mol B are structurally ordered due to
the crystal packing interactions and are visible in the electron
density map, these nucleotides are not recognized by Cas9
(data not shown). These observations suggested that the 30-
NCC-50 sequence complementary to the 50-NGG-30 PAM is not
recognized by Cas9 and are consistent with previous biochem-
ical data showing that Cas9-catalyzed DNA cleavage requires
the 50-NGG-30 PAM on the noncomplementary strand, but not
the 30-NCC-50 sequence on the complementary strand (Jinek
et al., 2012).
Previous studies showed that, although sgRNA with a 48 nt
tracrRNA tail (referred to as sgRNA(+48)) is the minimal region
for the Cas9-catalyzed DNA cleavage in vitro (Jinek et al.,
2012), sgRNAs with extended tracrRNA tails, sgRNA(+67) andsgRNA(+85), dramatically improved the Cas9 cleavage activity
in vivo (Hsu et al., 2013). The present structure revealed that
sgRNA(+48), sgRNA(+67), and sgRNA(+85) contain stem loop
1, stem loops 1–2, and stem loops 1–3, respectively (Figures
4A and 4B). These observations indicated that, whereas stem
loop 1 is essential for the formation of the functional Cas9-
sgRNA complex, stem loops 2 and 3 further support the stable
complex formation and enhance the stability of the sgRNA,
thus improving the in vivo activity.
To determine the significance of each sgRNA structural
component on the Cas9 function, we tested a number of
sgRNAs with mutations in the repeat:anti-repeat duplex, stem
loops 1–3, and the linker between stem loops 1 and 2. Our results
revealed that, whereas stem loops 2 and 3 as well as the linker
region can tolerate a large number of mutations, the repeat:
anti-repeat duplex and stem loop 1 are critical for the Cas9 func-
tion (Figure 4D). Moreover, the sgRNA sequence can tolerate a
large number of mutations (Figure 4D, reconstructed sgRNA).
These results highlight the functional significance of the struc-
ture-dependent recognition of the repeat:anti-repeat duplex by
Cas9.
The Conserved Arginine Cluster on the Bridge Helix Is
Critical for sgRNA:DNA Recognition
The sgRNA guide region is primarily recognized by the REC lobe
(Figure 5). The backbone phosphate groups of the guide region
(nucleotides 2, 4–6, and 13–20) interact with the REC1 domain
(Arg165, Gly166, Arg403, Asn407, Lys510, Tyr515, and
Arg661) and the bridge helix (Arg63, Arg66, Arg70, Arg71,
Arg74, and Arg78) (Figure 6A). The 20-hydroxyl groups of G1,
C15, U16, and G19 hydrogen bond with Val1009, Tyr450,
Arg447/Ile448, and Thr404, respectively (Figure 6A). These
observations suggested that the Watson-Crick faces of eight
PAM-proximal nucleotides in the Cas9-bound sgRNA are
exposed to the solvent, thus serving as a nucleation site for
pairing with the complementary strand of the target DNA. This
is consistent with previous reports that the 10–12 bp PAM-prox-
imal ‘‘seed’’ region is critical for the Cas9-catalyzed DNA cleav-
age (Cong et al., 2013; Fu et al., 2013; Hsu et al., 2013; Jinek
et al., 2012; Mali et al., 2013a; Pattanayak et al., 2013).
A mutational analysis demonstrated that the R66A, R70A,
and R74A mutations on the bridge helix markedly reduced the
DNA cleavage activities (Figure 6B), highlighting the functional
significance of the recognition of the sgRNA ‘‘seed’’ region by
the bridge helix. Although Arg78 and Arg165 also interact with
the ‘‘seed’’ region, the R78A and R165A mutants showed only
moderately decreased activities (Figure 6B). These results are
consistent with the fact that Arg66, Arg70, and Arg74 form
multiple salt bridges with the sgRNA backbone, whereas Arg78
and Arg165 form a single salt bridge with the sgRNA backbone
(Figure 6A). The cluster of arginine residues on the bridge helix
is highly conserved among the Cas9 proteins in the type II-A–C
systems (Figures S4 and S5), suggesting that the bridge helix
is a universal structural feature of the Cas9 proteins. This
notion is supported by the previous observation that a
strictly conserved arginine residue, equivalent to Arg70 of
S. pyogenes Cas9, is essential for the function of Francisella
novicida Cas9 in the type II-B system (Sampson et al., 2013).Cell 156, 935–949, February 27, 2014 ª2014 Elsevier Inc. 941
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(A) Schematic representation of the sgRNA:target DNA complex. The guide and repeat regions of the crRNA sequence are colored sky blue and blue,
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respectively. The numbering of the 30 tails of the tracrRNA is shown on a red background. Watson-Crick and non-Watson-Crick base pairs are indicated by black
and gray lines, respectively. Disordered nucleotides are boxed by dashed lines.
(B) Structure of the sgRNA:target DNA complex.
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Figure 5. Schematic Representation of
sgRNA:target DNA Recognition by Cas9
Residues that interact with the sgRNA:DNA via
their main chain are shown in parentheses.
Note that water-mediated hydrogen-bonding in-
teractions are not shown, for clarity.Moreover, the alanine mutations of the repeat:anti-repeat
duplex-interacting residues (Arg75 and Lys163) and the stem-
loop-1-interacting residue (Arg69) resulted in decreased DNA
cleavage activity (Figure 6B), confirming the functional impor-
tance of the recognition of the repeat:anti-repeat duplex and
stem loop 1 by Cas9.
The sgRNA guide region is recognized by Cas9 in a sequence-
independentmanner, except for the U16-Arg447 andG18-Arg71
interactions (Figures 5 and 6A). This base-specific G18-Arg71
interaction may partly explain the observed preference of Cas9
for sgRNAs with guanines in the four PAM-proximal guide re-
gions (Wang et al., 2014).(C) Close-up view of the repeat:anti-repeat duplex and the three-way junction. Key interactions are shown w
(D) Effects of sgRNA mutations on the ability to induce indels. Base changes from the sgRNA(+85) scaffold
indicating unaltered bases. n = 3; error bars show mean ± SEM; p values based on unpaired Student’s t tes
See also Figure S6.
Cell 156, 935–949,The REC1 and RuvC Domains
Facilitate RNA-Guided DNA
Targeting
Cas9 recognizes the 20 bp guide:target
heteroduplex in a sequence-independent
manner (Figure 5). The backbone phos-
phate groups of the target DNA (nucleo-
tides 10, 90–110, 130, and 200) interact
with the REC1 (Asn497, Trp659, Arg661,
and Gln695), RuvC (Gln926), and PI
(Glu1108) domains. The C20 atoms of
the target DNA (nucleotides 50, 70, 80,
110, 190, and 200) form van derWaals inter-
actions with the REC1 domain (Leu169,
Tyr450, Met495, Met694, and His698)
and the RuvC domain (Ala728) (Figure 5).
These interactions are likely to contribute
toward the ability of Cas9 to discriminate
between DNA and RNA targets. The ter-
minal base pair of the guide:target
heteroduplex (G1:C200) is recognized by
the RuvC domain via end-capping inter-
actions (Figure 6C); the sgRNA G1 and
target DNA C200 nucleobases interact
with the Tyr1013 and Val1015 side
chains, respectively, whereas the 20-hy-
droxyl and phosphate groups of sgRNA
G1 interact with Val1009 and Gln926,
respectively. These end-capping inter-
actions are consistent with the previous
observation that Cas9 recognizes a
17–20 bp guide:target heteroduplex andthat extended guide sequences are degraded in cells and do
not contribute to improving sequence specificity (Ran et al.,
2013). Taken together, these structural findings explain the
RNA-guided DNA-targeting mechanism of Cas9.
The Repeat:Anti-Repeat Duplex Is Recognized by the
REC and NUC Lobes in a Sequence-Dependent Manner
In contrast to the sequence-independent recognition of the
sgRNA guide region, sequence-dependent interactions exist
between Cas9 and the repeat:anti-repeat duplex (Figures 5,
6D, and 6E). The nucleobases of U23/A49 and A42/G43
hydrogen bond with the side chain of Arg1122 and theith gray dashed lines.
are shown at the respective positions, with dashes
t; N.D., not detectable; n.s., not significant.
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main-chain carbonyl group of Phe351, respectively (Figure 6D).
The nucleobase of the flipped U44 is sandwiched between
Tyr325 and His328, with its N3 atom hydrogen bonded with
Tyr325, whereas the nucleobase of the unpaired G43 stacks
with Tyr359 and hydrogen bonds with Asp364 (Figure 6E).
The present structure revealed that the repeat:anti-repeat
duplex is recognized by the REC lobe, which is divergent in
both sequence and length among the Cas9 orthologs within
the type II-A–C systems (Figures S4 and S5). This structural
finding explains the previous observation that Cas9 and sgRNA
are interchangeable only between closely related type II systems
(Fonfara et al., 2013). The three PAM-distal base pairs (C30:G39–
A32:U37) are not recognized by Cas9 and protrude from the
complex (Figure 5), consistent with a proposed model in which
the Cas9-bound repeat:anti-repeat duplex is processed by the
host RNase III enzyme (Deltcheva et al., 2011).
The nucleobases of G21 and U50 in the G21:U50 wobble pair
stack with the terminal C20:G10 pair in the guide:target hetero-
duplex and Tyr72 on the bridge helix, respectively, with the
U50 O4 atom hydrogen bonded with Arg75 (Figure 6D). Notably,
A51 adopts the syn conformation and is oriented in the direction
opposite to U50 (Figures 4C and 6F). The nucleobase of A51 is
sandwiched between Phe1105 and U63, with its N1, N6, and
N7 atoms hydrogen bonded with G62, Gly1103, and Phe1105,
respectively (Figure 6F). Whereas the repeat:anti-repeat du-
plexes have diverse sequences and lengths among the type
II-A–C systems, the G:U base pair at the three-way junction is
highly conserved among the repeat:anti-repeat duplexes in
these three systems (Fonfara et al., 2013), suggesting that this
wobble pairing is a universal structural feature involved in the
three-way junction formation.
To verify the importance of the sequence-dependent recogni-
tion of the repeat:anti-repeat duplex by Cas9, we evaluated the
effects of repeat:anti-repeat mutations on the Cas9-mediated
DNA cleavage (Figure 6B). The replacement of G43, which forms
base-specific hydrogen bonds with Phe351 and Asp364, with
cytosine reduced the Cas9 activity by greater than 3-fold. In
addition, the replacement of the flipped U44 with guanine re-
sulted in a >5-fold drop in the cleavage activity, whereas the
replacement of U44 with another pyrimidine base (cytosine) did
not significantly affect the cleavage activity (Figure 6B). These
results confirmed the functional importance of the base-specific
recognition of G43 and U44 by Cas9.
StemLoops 1–3Reinforce the Interaction betweenCas9
and sgRNA
Stem loop 1 is primarily recognized by the REC lobe, together
with the PI domain (Figure 5). The backbone phosphate groups
of stem loop 1 (nucleotides 52, 53, and 59–61) interact with the
REC1 domain (Leu455, Ser460, Arg467, Thr472, and Ile473),
the PI domain (Lys1123 and Lys1124), and the bridge helix
(Arg70 and Arg74), with the 20-hydroxyl group of G58 hydrogenFigure 6. sgRNA:Target DNA Recognition by Cas9
(A and C–J) Recognition of the guide (A), the guide:target heteroduplex (C), the rep
(H), stem loop 2 (I), and stem loop 3 (J). Hydrogen bonds and salt bridges are sh
(B) Effects of Cas9 (top) and sgRNA (bottom) mutations on the ability to induce ind
t test; N.D., not detectable; n.s., not significant.bonded with Leu455 (Figure 6G). A52 interacts with Phe1105
through a face-to-edge p-p stacking interaction (Figure 6F),
and the flipped U59 nucleobase hydrogen bonds with Asn77
(Figure 6G).
The single-stranded linker and stem loops 2 and 3 are primarily
recognized by the NUC lobe (Figure 5); in contrast, stem loop 1
and the guide:target/repeat:anti-repeat duplexes are recognized
by both the REC and NUC lobes. The backbone phosphate
groups of the linker (nucleotides 63–65 and 67) interact with
the RuvC domain (Glu57, Lys742, and Lys1097), the PI domain
(Thr1102), and the bridge helix (Arg69), with the 20-hydroxyl
groups of U64 and A65 hydrogen bonded with Glu57 and
His721, respectively (Figure 6H). The C67 nucleobase forms
two hydrogen bonds with Val1100 (Figure 6H).
Stem loop 2 is recognized by Cas9 via the interactions be-
tween the NUC lobe and the non-Watson-Crick A68:G81 pair,
which is formed by direct (between the A68 N6 and G81 O6
atoms) and water-mediated (between the A68 N1 and G81 N1
atoms) hydrogen-bonding interactions (Figure 6I). The A68 and
G81 nucleobases contact Ser1351 and Tyr1356, respectively,
whereas the A68:G81 pair interacts with Thr1358 via a water-
mediated hydrogen bond (Figure 6I). The 20-hydroxyl group of
A68 hydrogen bondswith His1349, whereas theG81 nucleobase
hydrogen bonds with Lys33 (Figure 6I).
Stem loop 3 interacts with the NUC lobe more extensively, as
compared to stem loop 2 (Figure 5). The backbone phosphate
group of G92 interacts with the RuvC domain (Arg40 and
Lys44), whereas the G89 and U90 nucleobases hydrogen bond
with Gln1272 and Glu1225/Ala1227, respectively (Figure 6J).
The A88 and C91 nucleobases are recognized by Asn46 via mul-
tiple hydrogen-bonding interactions (Figure 6J).
Structural Flexibility of Cas9 and sgRNA
Although the HNH domain cleaves the complementary strand of
the target DNA at a position 3 nt upstream of the PAM sequence
(Gasiunas et al., 2012; Jinek et al., 2012), in the present structure,
the HNH domain is located away from the scissile phosphate
group of the bound complementary strand (Figure 7A). A struc-
tural comparison of Mol A and Mol B provided mechanistic in-
sights into complementary strand cleavage by the HNH domain.
In Mol A, the HNH domain is followed by the a39 helix of the
RuvC domain, which is connected to the a40 helix by the a39-
a40 linker (residues 919–925) (Figure 7A). In Mol A, residues
913–925 form the C-terminal portion of the a39 helix and the
a39-a40 linker, whereas in Mol B, these residues form an
extended a helix, which is directed toward the cleavage site
of the complementary strand (Figure 7A). These observations
suggested that the HNH domain can approach and cleave the
target DNA through conformational changes in the segment
connecting the HNH and RuvC domains.
The structural comparison further revealed the conforma-
tional flexibility between the REC and NUC lobes (Figure 7B).eat (D), the anti-repeat (E), the three-way junction (F), stem loop 1 (G), the linker
own as dashed lines. In (A), the target DNA is omitted, for clarity.
els. n = 3; error bars showmean ± SEM; p values based on unpaired Student’s
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Figure 7. Structural Flexibility of the Complex and a Model for RNA-Guided DNA Cleavage by Cas9
(A) Structural comparison of Mol A and Mol B. In Mol A (left), the disordered linker between the RuvC and HNH domains is indicated by a dotted line. In Mol B
(right), the disordered HNH domain is shown as a dashed circle. The flexible connecting segment (a39 and a40) in the RuvC domain is colored orange.
(B) Superimposition of the Cas9 proteins inMol A andMol B. The two complexes are superimposed based on the core b sheet of the two RuvC domains. The HNH
domain and the bound sgRNA:target DNA complex were omitted, for clarity.
(C) Superimposition of the sgRNA:target DNA complex inMol A andMol B. After superimposition of the two complexes as in (B), theCas9 proteins were omitted to
show the sgRNA:target DNA complex.
(D) Molecular surface of Cas9. The HNH domain and the sgRNA:target DNA complex were omitted, for clarity.
(E) Model of RNA-guided DNA cleavage by Cas9.As compared to Mol A, Mol B adopts a more open conforma-
tion in which the two lobes are rotated by 15 at a hinge loop
between the bridge helix and strand b5 in the RuvC domain946 Cell 156, 935–949, February 27, 2014 ª2014 Elsevier Inc.(Figure 7B). The bound sgRNA also undergoes an accompa-
nying conformational change at the linker, which interacts
with the hinge loop (Figure 7C). We also observed the
concomitant displacement of the b17-b18 loop of the PI
domain, which interacts with the repeat:anti-repeat duplex
and the a2-a3 loop of the REC1 domain (Figure 7B). Notably,
there is no direct contact between the two lobes in the present
structure, except for the interactions between the a2-a3 and
b17-b18 loops (Figure 7D), suggesting that Cas9 is highly flex-
ible in the absence of the sgRNA. The flexible nature of Cas9 is
likely to play a role in the assembly of the Cas9-sgRNA-DNA
ternary complex.
DISCUSSION
The present structure revealed that the 20 bp heteroduplex,
formed by the sgRNA guide region and the complementary
strand of the target DNA, is accommodated in the positively
charged groove at the interface between the REC and NUC
lobes, with the scissile phosphate group of the target DNA
properly positioned for cleavage by the HNH domain. Although
the present structure does not contain the noncomplementary
DNA strand, the position of the bound complementary strand
suggested that the scissile phosphate of the noncomplementary
strand is located in the vicinity of the active site of the RuvC
domain, consistent with previous biochemical data (Gasiunas
et al., 2012; Jinek et al., 2012). Furthermore, our structural and
functional analyses indicated that the PI domain participates in
the PAM recognition.
Based on these observations, we propose a model for the
Cas9-catalyzed RNA-guided DNA cleavage (Figure 7E). Cas9
recognizes the PAM-proximal guide region and the repeat:
anti-repeat duplex of sgRNA to form the Cas9-sgRNA binary
complex. The binary complex subsequently recognizes the
DNA sequence complementary to the 20 nt guide region of the
bound sgRNA to form the final Cas9-sgRNA-target DNA ternary
complex. Prior to the ternary complex formation, the PI domain
recognizes the PAM sequence on the noncomplementary
strand, thereby triggering the R loop formation. Upon the assem-
bly of the ternary complex, the mobile HNH domain approaches
and cleaves the complementary strand in the guide:target
heteroduplex, whereas the RuvC domain cleaves the single-
stranded, noncomplementary strand. Biochemical studies indi-
cated that PAM recognition by Cas9 is important for both the
binding and cleavage of the target DNA, suggesting that the
Cas9-sgRNA complex may indeed undergo an inactive-to-
active conformational transition upon PAM recognition (Gasiu-
nas et al., 2012; Sternberg et al., 2014). This notion is consistent
with the fact that the present structure is likely to represent an
inactive state, where the HNH domain is located away from the
complementary strand.
The present crystal structure provides a critical step toward
understanding the molecular mechanism of RNA-guided DNA
targeting by Cas9. Further structural and functional studies
with S. pyogenes Cas9 or related orthologs, including the
structural elucidation of the Cas9-sgRNA-DNA ternary complex
containing the noncomplementary strand, will be important for
illuminating the mechanisms of PAM recognition, the conforma-
tional changes occurring upon PAM recognition, and the
mismatch tolerance between the guide:target heteroduplex.
However, this study has provided a useful scaffold for therational engineering of Cas9-based genomemodulating technol-
ogies. For example, we created an S. pyogenes Cas9 truncation
mutant (Figure 2B) that will facilitate the packaging of Cas9 into
size-constrained viral vectors for in vivo and therapeutic applica-
tions. Moreover, future engineering of the PI domain may allow
us to program the PAM specificity, improve the target site recog-
nition fidelity, and increase the versatility of the Cas9 genome en-
gineering platform.EXPERIMENTAL PROCEDURES
Detailed experimental procedures are described in the Extended Experimental
Procedures, and related sequences are shown in Data S1.
The S. pyogenes Cas9 D10A/C80L/C574E/H840A mutant (residues
1–1368) was expressed in Escherichia coli Rosetta 2 (DE3) (Novagen) and
purified by chromatography on Ni-NTA Superflow (QIAGEN), Mono S (GE
Healthcare), and HiLoad Superdex 200 16/60 (GE Healthcare) columns.
The SeMet-labeled Cas9 protein was expressed in E. coli B834 (DE3) and
was purified using a similar protocol as for the native protein. The 98 nt
sgRNA was in vitro transcribed with T7 polymerase and was purified by
10% denaturing polyacrylamide gel electrophoresis. The 23 nt target DNA
was purchased from Sigma-Aldrich. The purified Cas9 protein was mixed
with sgRNA and DNA (molar ratio, 1:1.5:2.3), and the complex was purified
by gel filtration chromatography on a Superdex 200 Increase column (GE
Healthcare).
The purified complex was crystallized at 20C by the hanging-drop vapor
diffusion method. Crystals were obtained by mixing 1 ml of complex solution
(A260 nm, 15) and 1 ml of reservoir solution (13% PEG 3,350, 100 mM Tris-HCl
[pH 8.0], 200 mM ammonium acetate, and 100 mM NDSB-256). The SeMet-
labeled protein was crystallized under conditions similar to those for the native
protein. X-ray diffraction data were collected at 100 K on the beamlines
BL32XU and BL41XU at SPring-8 (Hyogo, Japan). The structure was deter-
mined by the SAD method, using the 2.6 A˚ resolution data set from the Se-
Met-labeled crystals. The final model was refined using the 2.5 A˚ resolution
native data set.
The human embryonic kidney (HEK) cell line 293FT (Life Technologies) was
seeded into 24-well plates (Corning) at a density of 120,000 cells/well 24 hr
prior to transfection. Cells at 70%–80% confluency were transfected using
Lipofectamine 2000 (Life Technologies), according to the manufacturer’s
recommended protocol. The Cas9 plasmid (400 ng) and the U6::sgRNA PCR
product (100 ng) were transfected into each well. Genomic modifications
were evaluated using the SURVEYORnuclease assay, as described previously
(Cong et al., 2013).ACCESSION NUMBERS
The atomic coordinates of the Cas9-sgRNA-DNA ternary complex have been
deposited in the Protein Data Bank with the PDB code 4OO8.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, two tables, and one data file and can be found with this article online
at http://dx.doi.org/10.1016/j.cell.2014.02.001.
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